The invention provides a 
zolmitriptan sublingual tablet, which is characterized in that it contains the main 
drug zolmitriptan, a disintegrating agent and a filler. In every 1000 sublingual tablets, the content of 
zolmitriptan is 1  -50g, the content of disintegrating agent is 2-20g, the content of filler is 40-200g; it also contains 0-20g of corrective agent, 10-60g of binder and 0.5-5g of 
lubricant.  The present invention utilizes the characteristics of non-keratinized sublingual mucosa, rich capillaries, and fast 
blood flow, aiming at the absorption of zolmitriptan ordinary tablets through the 
gastrointestinal tract, slow 
onset of action, first-pass effect, and low 
bioavailability.  The deficiencies of advanced prior art, zolmitriptan is made into 
sublingual tablet, can make it absorb through sublingual mucosa, directly enter 
blood circulation through 
jugular vein and 
superior vena cava, take effect rapidly; Avoid 
oral administration  The first-pass effect improves 
bioavailability and ensures 
curative effect.  Moreover, water is not needed when taking the 
medicine, and it is placed under the tongue to contain it, so it is convenient to take and has a good taste.  With the characteristics of 
rapid onset of action, convenient administration and high 
bioavailability, it can provide patients with a new treatment option and fill the gap in the market.